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Abstract: The bovine immune system is known for its unusual traits relating to immunoglobulin 
and antiviral responses. Peptidylarginine deiminases (PADs) are phylogenetically conserved 
enzymes that cause post-translational deimination, contributing to protein moonlighting in health 
and disease. PADs also regulate extracellular vesicle (EV) release, forming a critical part of cellular 
communication. As PAD-mediated mechanisms in bovine immunology and physiology remain to 
be investigated, this study profiled deimination signatures in serum and serum-EVs in Bos taurus. 
Bos EVs were poly-dispersed in a 70–500 nm size range and showed differences in deiminated 
protein cargo, compared with whole sera. Key immune, metabolic and gene regulatory proteins 
were identified to be post-translationally deiminated with some overlapping hits in sera and EVs 
(e.g., immunoglobulins), while some were unique to either serum or serum-EVs (e.g., histones). 
Protein–protein interaction network analysis of deiminated proteins revealed KEGG pathways 
common for serum and serum-EVs, including complement and coagulation cascades, viral infection 
(enveloped viruses), viral myocarditis, bacterial and parasitic infections, autoimmune disease, 
immunodeficiency intestinal IgA production, B-cell receptor signalling, natural killer cell mediated 
cytotoxicity, platelet activation and hematopoiesis, alongside metabolic pathways including 
ferroptosis, vitamin digestion and absorption, cholesterol metabolism and mineral absorption. 
KEGG pathways specific to EVs related to HIF-1 signalling, oestrogen signalling and biosynthesis 
of amino acids. KEGG pathways specific for serum only, related to Epstein–Barr virus infection, 
transcription mis-regulation in cancer, bladder cancer, Rap1 signalling pathway, calcium signalling 
pathway and ECM-receptor interaction. This indicates differences in physiological and pathological 
pathways for deiminated proteins in serum-EVs, compared with serum. Our findings may shed 
light on pathways underlying a number of pathological and anti-pathogenic (viral, bacterial, 
parasitic) pathways, with putative translatable value to human pathologies, zoonotic diseases and 
development of therapies for infections, including anti-viral therapies. 
Keywords: peptidylarginine deiminases (PADs); protein deimination; bovine (Bos taurus); 
extracellular vesicles (EVs); immunity; metabolism; anti-viral 
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1. Introduction 
Cattle are mammalian ruminants of the genus Bos, comprised of domesticated and wild cattle 
with five main extant (living) species [1]. The lifespan of Bos is 18-25 years in the wild and as cattle 
are valuable livestock that form an important part of food security, bovine research is important for 
livestock management. Furthermore cows fall under a group of long-lived mammals that display 
considerable cancer resistance [2]. With considerably long life spans and unusual immunological 
characteristics cows may hold information for molecular pathways underlying such physiological 
traits. The bovine immune system has received considerable attention in the medical field due to its 
unique immunoglobulin traits, including exceptional ability to reach recessed viral epitopes on 
enveloped viruses. Therefore, a particular research focus has been on their unusual ultralong CDR3H 
“cattlebodies”, which are being developed for immunotherapy, including against retroviral 
infections such as HIV [3–5]. 
Peptidylarginine deiminases (PADs) are phylogenetically conserved calcium-dependent 
enzymes which cause an irreversible post-translational conversion of arginine to citrulline in target 
proteins. This modification causes structural, and sometimes functional, changes of target 
cytoskeletal, cytoplasmic, mitochondrial and nuclear proteins, including loss or gain of function or 
denaturation. Deimination can furthermore cause the generation of neo-epitopes and affect gene 
regulation [6–11]. This post-translational modification is most effective on beta-sheets and disordered 
proteins [7] and can also facilitate protein moonlighting, where one polypeptide can exhibit 
multifaceted functions that are physiologically relevant. As this is an evolutionarily acquired 
phenomenon, moonlighting facilitated by post-translational changes, such as deimination, may 
contribute to protein’s diverse and conserved functions throughout phylogeny [12,13]. PADs are 
identified throughout phylogeny from bacteria to mammals. In mammals, five tissue specific PAD 
isozymes with deimination activity are described, three in chicken and alligator, one in bony and 
cartilaginous fish [6,14–17], and PAD homologues (arginine deiminases, ADI) in parasites [18], fungi 
[19] and bacteria [20,21]. While in Bos taurus five PAD isozymes have been reported: PAD1 
(NP_001094742.1), PAD2 (NP_001098922.1), PAD3 (XP_010800991.1), PAD4 (NP_001179102.1) and 
PAD6 (XP_002685843.1), few studies, besides assessment of cattle PAD ability to deiminate human 
myelin basic protein [22] and inhibitory effects of paclitaxel on PAD activity in bovine brain extract 
[23], have hitherto been carried out on PAD protein function, or on putative physiological relevance 
for PAD-mediated post-translational deimination in cattle. 
PADs play important roles in a range of pathologies, including chronic, autoimmune and 
neurodegenerative diseases, as well as in cancer [9–11,24]. PADs also play roles in hypoxia and CNS 
regeneration [25–29], and PAD-mediated mechanisms have been related to ageing [30,31]. 
Importantly, PADs have also been implicated in infection, including sepsis, endotoxemia [32–39], in 
antibiotic resistance [21] and other anti-pathogenic responses, including anti-viral ones [37,40,41]. 
Roles for anti-viral responses via PAD-mediated neutrophil extracellular trap formation (NETosis) 
have furthermore been identified in cattle respiratory syncytial virus disease, via the detection of 
deiminated/citrullinated histone H3 [42]. Roles for PADs in tissue remodeling and immunity have 
also recently been described [15,16,43]. PADs have furthermore been identified as phylogenetically 
conserved key regulators of cellular extracellular vesicle (EV) release [21,44–46]. EV-mediated cellular 
communication is a phylogenetically conserved phenomenon [47], with EVs transferring cargo 
proteins and genetic material characteristic of the cells of origin [11,48–51]. As EV cargo is comprised 
of a large range of proteins, enzymes and genetic material, and as EVs can easily be isolated from a 
range of body fluids, including serum and plasma, EV signatures can be useful biomarkers [52,53].  
While work on EVs has largely focused on human pathologies [53], EVs are gaining increasing 
interest also in veterinary medicine, including in cattle [47,54–57]. Studies on EVs in cattle have been 
in relation to host-pathogen interactions [58–61], including in bovine respiratory disease [62,63] and 
in response to infection [64,65], as well as for export of viral proteins [66–68]. EV research in cattle 
has furthermore been in relation to the estrous cycle, fertility and reproduction [56,69–74], as well as 
for roles during embryonic development [75–78]. Bovine milk EVs have been assessed for biological 
activities [79–83], for the application of milk EVs as safe drug delivery vehicles [84–86], as well as 
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assessment of viral transfer via milk to calves [87]. Bovine milk EVs have also been investigated as 
an anti-inflammatory treatment in autoimmune disease [88,89] and in necrotizing enterocolitis [90]. 
Cattle EVs have furthermore been investigated in relation to neurological disease, including bovine 
spongiform encephalopathy (BSE) [54].  
A recent body of comparative studies with respect to EVs and EV cargo has been performed in 
a range of taxa throughout the phylogenetic tree, including with a particular emphasis on deiminated 
protein cargo by our group [17,91–99] Hitherto though, no such evaluation of post-translational 
protein cargo in cattle serum or serum-EVs has been carried out and therefore warrants further 
exploration. In the current study, post-translationally deiminated protein signatures were assessed 
in serum and serum-EVs of Bos taurus. We report for the first time post-translational deimination of 
key immune, metabolic and nuclear proteins in cattle, and identify differences in KEGG pathways 
enriched for deiminated proteins in serum-EVs compared to whole serum. Our findings provide 
novel insight into the unusual immunological traits of cattle, including a new angle on their unusual 
anti-viral activity. Our findings further current understanding of protein moonlighting via 
deimination in physiological and immunological pathways, underlying anti-pathogenic responses 
throughout phylogeny. 
2. Results 
2.1. Characterisation of Bovine Serum-EVs  
Bos taurus serum-EVs were assessed by nanoparticle tracking analysis (NTA) for particle 
numbers and size distribution using the NanoSight NS300 system, revealing a poly-dispersed 
population of EVs in the size range of 70–500 nm (Figure 1A). Further characterization was performed 
by western blotting using the EV-specific markers CD63 and Flot-1 (Figure 1B), which showed 
positive at protein band sizes corresponding to what is observed for these EV markers in other taxa, 
including in human [17,46,91–93,96–99], and by transmission electron microscopy (TEM), confirming 
typical EV morphology (Figure 1C). Some variation was observed between the three individuals with 
respect to EV yield, ranging from 1.72 × 1010 to 2.46 × 1010 per ml, and modal EV size, which fell in the 
range of 146–165 nm.  
 
Figure 1. Extracellular vesicle profiling in bovine serum. (A) Nanoparticle tracking analysis shows a 
size distribution of plasma-EVs from Bos taurus in the size range of 70 to 500 nm, with main peaks at 
approximately 120-240 nm. (B) Transmission electron microscopy (TEM) analysis of bovine serum-
derived EVs shows typical EV morphology; scale bar is 50 nm in all figures. (C) Western blotting 
analysis confirms that bovine EVs are positive for the phylogenetically conserved EV-specific markers 
CD63 and Flot-1, showing positive at expected molecular weight size corresponding to what is 
observed in other taxa (kDa = kilodaltons). 
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2.2. PAD Protein Homologues and Deiminated Proteins in Bovine Serum and Serum-EVs 
For assessment of total deiminated proteins present in serum, F95-positive proteins were 
detected by western blotting in the size range of mainly 50–150 kDa (Figure 2A). Following 
immunoprecipitation for F95-enrichment of deiminated proteins in serum and serum-EVs, 
silverstaining revealed F95-enriched protein bands between 15–150 kDa in serum and in EVs protein 
bands were observed mainly in the size range of 50–150 kDa (Figure 2B). For assessment of bovine 
PAD protein homologues, anti-human PAD-isozyme specific antibodies were used for western 
blotting, identifying a positive protein band at 70–75 kDa mainly cross-reacting with anti-human 
PAD4 antibody in bovine serum (Figure 2C). A neighbor-joining phylogeny tree was furthermore 
constructed for bovine PADs (PAD1, NP_001094742.1; PAD2, NP_001098922.1; PAD3, 
XP_010800991.1; PAD4, NP_001179102.1 and PAD6, XP_002685843.1) compared with human PADs 
(PAD1, NP_037490.2; PAD2, NP_031391.2; PAD3, NP_057317.2; PAD4, NP_036519.2 and PAD6, 
NP_997304.3), using Clustal Omega (https://www.ebi.ac.uk/Tools/msa/clustalo/), showing that the 
individual bovine and human PAD isoforms clustered together (Figure 2D).  
 
Figure 2. Deiminated proteins and peptidylarginine deiminases (PADs) in bovine serum. (A) Total 
deiminated proteins were identified in bovine serum using the pan-deimination specific F95 
antibody. (B) F95-enriched IP fraction from bovine serum and serum-extracellular vesicles (EVs), 
shown by silver-staining. (C) Immunodetection of PAD homologues in bovine sera by western 
blotting, using anti-human PAD2, PAD3 and PAD4 antibodies. (D) A neighbor-joining phylogeny 
tree for bovine and human PAD isozymes. 
2.3. LC-MS/MS Analysis of Deiminated Proteins in Bovine Serum and Serum-EVs 
Protein identification of deiminated proteins in bovine serum and serum-EVs was carried out 
using F95-enrichment and LC-MS/MS analysis, searching for species-specific protein hits using the 
Bos taurus protein database. In serum, 118 species-specific deiminated protein hits were identified 
and 31 were specific to total serum only (Table 1; see detailed analysis for all hits in Supplementary 
Table S1). In serum-EVs, 179 species-specific deiminated protein hits were identified and 90 were 
specific to EVs only (Table 2; see detailed analysis for all hits in Supplementary Table S2).  
Table 1. Deiminated proteins in bovine serum (Bos taurus), as identified by F95-enrichment and LC-
MS/MS analysis. Deiminated proteins from serum were isolated by immunoprecipitation using the 
pan-deimination F95 antibody. The resulting F95-enriched eluate was then analysed by LC-MS/MS 
and peak list files submitted to Mascot. Bos taurus species-specific peptide sequence hits are listed, 
showing number of sequences for protein hits and total score. Blue highlighted rows indicate protein 
hits identified in whole sera only. Uncharacterised proteins based on LC-MS/MS search were further 
confirmed in STRING, based on the protein symbol, and protein identification from STRING, where 
retrieved, is shown in brackets ([]). For further full LC-MS/MS analysis of all protein hits see 
Supplementary Table S1. 
Protein Name Symbol Sequences Total Score (p < 0.05) 1 
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Serotransferrin G3X6N3 76 5712 
Serotransferrin Q29443 76 5711 
Complement factor H Q28085 77 5123 
Alpha-2-macroglobulin Q7SIH1 77 5079 
Serum albumin A0A140T897 59 3944 
Uncharacterised protein [complement factor H] F1MC45 54 3745 
Complement C3 Q2UVX4 68 3483 
Uncharacterised protein [ceruloplasmin] F1N076 44 2712 
Embryo-specific fibronectin 1 B8Y9S9 37 2263 
Hemopexin Q3SZV7 30 2019 
Uncharacterised protein [complement C4A] E1BH06 34 1997 
C4b-binding protein alpha chain Q28065 33 1841 
Kininogen-1 A0A140T8C8 23 1505 
Kininogen-1 P01044 22 1449 
Histidine-rich glycoprotein F1MKS5 26 1432 
Uncharacterised protein (uncharacterised) F1MJK3 26 1291 
Kininogen-2 P01045 19 1271 
Uncharacterised protein (uncharacterised) G3X7F3 16 1259 
Uncharacterised protein (uncharacterised) G3N0V0 19 1186 
Apolipoprotein A-I preproprotein V6F9A2 19 1122 
Uncharacterised protein (uncharacterised) F1MVK1 17 953 
SERPIND1 protein A6QPP2 16 865 
Uncharacterised protein (uncharacterised) F1MZ96 13 837 
Uncharacterised protein [Bos taurus immunoglobulin 
lambda-like polypeptide 1 (IGLL1)] 
F1MLW7 10 815 
Uncharacterised protein [Bos taurus immunoglobulin 
lambda-like polypeptide 1 (IGLL1)] 
F1MCF8 10 796 
Uncharacterised protein [Immunoglobulin heavy constant 
mu] 
G5E5T5 12 784 
Uncharacterised protein [Immunoglobulin heavy constant 
mu] 
G5E513 10 732 
Uncharacterised protein (uncharacterised) G3N0S9 12 648 
Histidine-rich glycoprotein P33433 12 623 
Alpha-2-antiplasmin P28800 11 531 
Uncharacterised protein (uncharacterised) F1MLW8 5 434 
Hemoglobin subunit beta P02070 6 422 
Vitamin D-binding protein F1N5M2 9 420 
Alpha-1-antiproteinase P34955 8 418 
Adiponectin Q3Y5Z3 6 411 
Uncharacterised protein (uncharacterised) F1MW79 7 403 
ECM1 protein A5PJT7 8 395 
Complement C1q subcomponent subunit B Q2KIV9 8 390 
Plasma kallikrein Q2KJ63 8 385 
Inter-alpha-trypsin inhibitor heavy chain H4 F1MMD7 6 367 
C1QC protein Q1RMH5 5 347 
Uncharacterised protein [Serpin A3-5; Serine protease 
inhibitor] 
G8JKW7 6 338 
Apolipoprotein A-IV F1N3Q7 7 338 
Inter-alpha-trypsin inhibitor heavy chain H2 F1MNW4 6 338 
Selenoprotein P P49907 6 323 
Plasminogen E1B726 6 302 
Complement C1q subcomponent subunit A Q5E9E3 5 300 
Uncharacterised protein [Bos taurus insulin-like growth 
factor binding protein, acid labile subunit (IGFALS)] 
F1MJZ4 6 277 
Thrombospondin-1 F1N3A1 7 273 
Serpin A3-3 G3N1U4 5 271 
Protein HP-20 homolog Q2KIT0 5 269 
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Uncharacterised protein (uncharacterised) G5E604 4 234 
Inter-alpha-trypsin inhibitor heavy chain H1 Q0VCM5 4 234 
Uncharacterised protein (uncharacterised) E1B805 5 232 
Uncharacterised protein (uncharacterised) G3MXD9 3 209 
Uncharacterised protein [Bos taurus immunoglobulin 
lambda-like polypeptide 1 (IGLL1)] 
G3N2D7 3 204 
Keratin, type II cytoskeletal 7 Q29S21 4 199 
Keratin, type I cytoskeletal 14 F1MC11 4 199 
Uncharacterised protein [Heparan sulfate proteoglycan 2] F1MER7 4 195 
Alpha-2-HS-glycoprotein 
cRAPR1|FETUA
_BOVIN 
4 190 
Uncharacterised protein (uncharacterised) G3N1H5 2 187 
Serpin A3-8 A0A0A0MP89 3 184 
Complement factor B P81187 4 183 
Protein AMBP F1MMK9 5 181 
Serpin A3-2 A2I7M9 4 180 
Antithrombin-III F1MSZ6 5 176 
Paraoxonase 1 Q2KIW1 4 174 
Gelsolin F1MJH1 3 171 
Uncharacterised protein (uncharacterised) G3N3Q3 2 168 
Complement C5a anaphylatoxin F1MY85 3 166 
Uncharacterised protein (uncharacterised) G5E5H2 3 162 
Serpin A3-7 A0A0A0MP92 4 160 
C1QTNF3 protein A7MB82 3 160 
Uncharacterised protein [Bos taurus serotransferrin-like] E1BI82 4 157 
Uncharacterised protein [Apolipoprotein B] E1BNR0 4 150 
Primary amine oxidase, liver isozyme Q29437 3 137 
Coagulation factor XI F1MUT4 2 127 
Hepatocyte growth factor-like protein E1BDW7 2 121 
Fibrinogen beta chain F1MAV0 3 108 
Immunoglobulin J chain Q3SYR8 2 107 
Uncharacterised protein (uncharacterised) G3MXB5 2 100 
Uncharacterised protein [CD5 molecule-like] F1N514 2 94 
Uncharacterised protein (uncharacterised) G3MXG6 2 94 
Complement component C9 Q3MHN2 2 87 
Complement component C6 F1MM86 3 86 
Uncharacterised protein (uncharacterised) G5E5V1 2 86 
Hemoglobin subunit alpha P01966 2 85 
Uncharacterised protein (uncharacterised) G3N028 2 75 
Fibrinogen alpha chain A5PJE3 1 74 
Vitronectin Q3ZBS7 2 73 
Alpha-1B-glycoprotein Q2KJF1 1 66 
Coagulation factor XII F1MTT3 1 65 
Uncharacterised protein (uncharacterised) F1MSF0 2 63 
Prothrombin P00735 1 61 
Uncharacterised protein [Nidogen 1] F1MWN3 1 57 
Protein HP-25 homolog 2 Q2KIU3 1 57 
Clusterin F1MWI1 1 55 
Contactin-1 F1MVI0 1 54 
Polymeric immunoglobulin receptor F1MR22 2 51 
Uncharacterised protein [Sperm associated antigen 9] F1MZ69 2 51 
Uncharacterised protein [Ankyrin repeat domain 11] E1BAT5 2 51 
Beta-2-glycoprotein 1 A0A140T843 1 50 
Carboxypeptidase N catalytic chain Q2KJ83 1 49 
Uncharacterised protein [complement component 8, alpha 
polypeptide (C8A)] 
F1MX87 1 48 
Fibrinogen gamma-B chain F1MGU7 1 48 
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Uncharacterised protein [ADAM metallopeptidase with 
thrombospondin type 1 motif, 13] 
F1MVP0 1 47 
Uncharacterised protein [Talin 1] F1MDH3 1 46 
Complement C1s subcomponent Q0VCX1 1 46 
Uncharacterised protein [CL43 - Collectin-43] F1MFY6 1 45 
Complement component C7 F1N045 1 44 
CLEC11A protein A5D7L1 1 43 
Uncharacterised protein [KCTD12 - Potassium channel 
tetramerization domain containing 12] 
G3N3D4 1 43 
Uncharacterised protein [BRIP1 - BRCA1 interacting protein 
C-terminal helicase 1] 
E1BNG9 1 39 
Cadherin-1 F1N619 1 39 
Ubiquitin carboxyl-terminal hydrolase isozyme L5 Q9XSJ0 1 38 
CPN2 protein A6QP30 1 37 
Acyl-coenzyme A thioesterase THEM4 A1A4L1 1 37 
Uncharacterised protein [SLAMF9 - SLAM family member 9] E1BNF9 1 36 
Uncharacterised protein [MED12; Mediator complex subunit 
12] 
F1MZ95 1 35 
Transthyretin O46375 1 33 
Voltage-dependent L-type calcium channel subunit beta-3 Q9MZL3 1 33 
1 Ions score is −10*Log(P), where P is the probability that the observed match is a random event. 
Individual ions scores > 31 indicated identity or extensive homology (p < 0.05). Protein scores were 
derived from ions scores as a non-probabilistic basis for ranking protein hits. 
Table 2. Deiminated proteins in serum-EVs of cow (Bos taurus) as identified by F95-enrichment. 
Deiminated proteins from serum-EVs were isolated by immunoprecipitation using the pan-
deimination F95 antibody. The resulting F95-enriched eluate was then analysed by LC-MS/MS and 
peak list files submitted to Mascot. Bos taurus species-specific peptide sequence hits are listed, 
showing number of sequences for protein hits and total score. Rows highlighted in pink indicate 
protein hits identified in serum-EVs only. Uncharacterised proteins based on LC-MS/MS search were 
further confirmed in STRING, based on the protein symbol, and protein identification from STRING, 
where retrieved, is shown in brackets ([]).For further full LC-MS/MS analysis of all protein hits see 
Supplementary Table S2. 
Protein Name Symbol Sequences Total Score (p < 0.05) 1 
Serotransferrin G3X6N3 75 4958 
Serotransferrin Q29443 74 4941 
Complement factor H Q28085 85 4700 
Alpha-2-macroglobulin Q7SIH1 77 4633 
Serum albumin A0A140T897 76 4604 
Complement C3 Q2UVX4 83 4258 
Uncharacterised protein (CFH - Complement 
factor H) 
F1MC45 61 3469 
Fibronectin G5E5A9 56 2492 
Uncharacterised protein (Ceruloplasmin) F1N076 37 1994 
Uncharacterised protein (uncharacterised) F1MJK3 38 1870 
Uncharacterised protein (C4A - Complement 
C4) 
E1BH06 35 1840 
C4b-binding protein alpha chain Q28065 36 1761 
Keratin, type II cytoskeletal 5 M0QVZ6 35 1750 
Hemopexin Q3SZV7 30 1594 
Keratin, type I cytoskeletal 14 F1MC11 29 1592 
Uncharacterised protein (uncharacterised) G3N0V0 25 1542 
Histidine-rich glycoprotein F1MKS5 26 1407 
Uncharacterised protein (keratin 33A (KRT33A)) F1MXG6 22 1311 
KRT33A protein A5PJJ1 22 1306 
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Keratin 31 Q148I8 22 1291 
Uncharacterised protein (uncharacterised) G3X7F3 20 1288 
Keratin, type II cuticular Hb1 Q148H4 25 1225 
Uncharacterised protein (keratin 34 (KRT34)) F1MSA6 21 1209 
Kininogen-1 A0A140T8C8 21 1188 
Kininogen-1 P01044 21 1164 
Uncharacterised protein (Desmoplakin) E1BKT9 27 1156 
Uncharacterised protein (keratin 86 (KRT86)) E1B898 22 1104 
Apolipoprotein A-I preproprotein V6F9A2 22 1101 
Uncharacterised protein (uncharacterised) F1MVK1 20 1066 
Uncharacterised protein (KRT6A - Keratin, type 
II cytoskeletal 59 kDa, component IV) 
M0QVY0 21 1049 
Kininogen-2 P01045 19 1042 
Uncharacterised protein (KRT3 - Keratin, type II 
cytoskeletal 68 kDa, component IB) 
G3MXL3 21 1034 
Junction plakoglobin Q8SPJ1 21 987 
Keratin, type II cytoskeletal Q08D91 19 971 
Uncharacterised protein (Immunoglobulin 
heavy constant mu) 
G5E5T5 16 938 
Keratin, type I cytoskeletal 17 A0A140T867 17 890 
Uncharacterised protein (IGLL1 - 
immunoglobulin lambda-like polypeptide 1) 
F1MCF8 12 886 
Uncharacterised protein (uncharacterised) F1MH40 13 872 
Uncharacterised protein (uncharacterised) F1MZ96 14 863 
Keratin 10 (Epidermolytic hyperkeratosis; 
keratosis palmaris et plantaris) 
A6QNZ7 15 854 
Uncharacterised protein (uncharacterised) F1MLW7 10 849 
Complement C4 P01030 16 826 
Uncharacterised protein (Immunoglobulin 
heavy constant mu) 
G5E513 15 810 
KRT15 protein Q17QL7 13 734 
Uncharacterised protein (uncharacterised) G3N0S9 14 631 
Keratin, type I cytoskeletal 19 P08728 12 625 
KRT4 protein A4IFP2 12 623 
SERPIND1 protein A6QPP2 12 606 
Uncharacterised protein (uncharacterised) F1MLW8 7 588 
Histidine-rich glycoprotein P33433 9 566 
Inter-alpha-trypsin inhibitor heavy chain H2 F1MNW4 12 554 
Inter-alpha-trypsin inhibitor heavy chain H4 F1MMD7 10 521 
Vitamin D-binding protein F1N5M2 12 517 
Antithrombin-III F1MSZ6 11 492 
Plasminogen P06868 14 485 
Apolipoprotein A-IV Q32PJ2 11 475 
Serpin A3-3 G3N1U4 9 442 
Complement factor B P81187 9 429 
C1QC protein Q1RMH5 8 428 
Complement C1q subcomponent subunit B Q2KIV9 7 413 
Uncharacterised protein (serotransferrin-like) E1BI82 8 411 
Uncharacterised protein (KRT16 - Keratin 16) G3X7W8 9 407 
Complement C1q subcomponent subunit A Q5E9E3 7 401 
Serpin A3-4 A2I7N0 9 383 
Alpha-1B-glycoprotein Q2KJF1 7 381 
Uncharacterised protein (uncharacterised) G3N3Q3 5 367 
Uncharacterised protein (Serpin A3-5) G8JKW7 7 366 
Keratin, type II cytoskeletal 78 A6QNX5 7 356 
Primary amine oxidase, liver isozyme Q29437 8 352 
Serpin A3-2 A2I7M9 7 333 
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Uncharacterised protein (uncharacterised) F1MW79 6 330 
Uncharacterised protein (uncharacterised) G3N1H5 5 325 
Uncharacterised protein (KRT77 - Keratin 77) G3MYU2 6 310 
Uncharacterised protein (uncharacterised) E1B805 7 309 
Uncharacterised protein (uncharacterised) G3MXG6 4 305 
Uncharacterised protein (uncharacterised) G3MXD9 5 300 
Uncharacterised protein (uncharacterised) G3N2P6 5 292 
Uncharacterised protein (insulin-like growth 
factor binding protein, acid labile subunit 
(IGFALS)) 
F1MJZ4 5 286 
Adiponectin Q3Y5Z3 5 282 
Alpha-2-antiplasmin P28800 7 271 
Protein AMBP F1MMK9 6 268 
Vitronectin Q3ZBS7 5 264 
Uncharacterised protein (uncharacterised) G5E604 5 254 
Desmoglein-1 F1MIW8 7 252 
Fibrinogen gamma-B chain F1MGU7 5 252 
Uncharacterised protein (uncharacterised) G3MY71 5 251 
Annexin A2 P04272 5 244 
Fibrinogen alpha chain A5PJE3 5 243 
Uncharacterised protein (uncharacterised) G3MWT1 3 241 
Glyceraldehyde-3-phosphate dehydrogenase P10096 6 238 
Serpin A3-7 A0A0A0MP92 5 218 
Plakophilin-1 Q28161 4 216 
Inter-alpha-trypsin inhibitor heavy chain H1 Q0VCM5 5 213 
Hemoglobin subunit beta P02070 4 212 
Alpha-1-antiproteinase P34955 4 209 
Keratin, type II A0JND2 4 198 
Actin, cytoplasmic 1 F1MRD0 5 197 
Keratin, type I cytoskeletal 28 Q148H6 4 194 
Thrombospondin-1 F1N3A1 6 192 
Keratin, type I cytoskeletal 20 F1MPK1 4 191 
ECM1 protein A5PJT7 5 188 
Uncharacterised protein (Bos taurus 
immunoglobulin lambda-like polypeptide 1 
(IGLL1)) 
G3N2D7 3 186 
Selenoprotein P P49907 5 184 
Uncharacterised protein (uncharacterised) A0A0A0MPA0 4 176 
Gelsolin F1MJH1 4 175 
Lactotransferrin P24627 4 169 
Fibrinogen beta chain F1MAV0 5 162 
Uncharacterised protein (uncharacterised) G5E5H2 3 156 
Protein HP-20 homolog Q2KIT0 3 151 
Uncharacterised protein (TGM1 - 
Transglutaminase 1) 
F1MBB7 2 143 
Actin, gamma-enteric smooth muscle F1MKC4 4 143 
Uncharacterised protein (CD5L - CD5 molecule-
like) 
F1N514 4 131 
Complement component C7 F1N045 4 128 
Uncharacterised protein (APOB - 
Apolipoprotein B) 
E1BNR0 4 119 
Arginase-1 Q2KJ64 3 119 
Alpha-S1-casein CASA1_BOVIN  2 115 
Uncharacterised protein (uncharacterised) G3N028 2 114 
Alpha-2-HS-glycoprotein cRAPR1|FETUA_BOVIN 2 106 
Paraoxonase 1 Q2KIW1 3 106 
Beta-2-glycoprotein 1 A0A140T843 2 97 
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Uncharacterised protein (uncharacterised) G5E5V1 2 89 
Uncharacterised protein (Histone H2B family) E1B7N8 2 88 
Complement component 1, r subcomponent A5D9E9 3 83 
Histone H2A A0A0A0MP90 2 80 
Uncharacterised protein (SLK-STE20-like kinase) G3X696 3 80 
Prothrombin P00735 2 79 
Peroxiredoxin-2 Q9BGI3 3 79 
Uncharacterised protein (uncharacterised) G3MZE0 1 69 
Uncharacterised protein (complement 
component 8, alpha polypeptide (C8A)) 
F1MX87 1 69 
Uncharacterised protein (C1orf68 - Chromosome 
1 open reading frame 68) 
G3N3D3 2 68 
Complement C5a anaphylatoxin F1MY85 2 63 
Uncharacterised protein (complement factor I 
(CFI)) 
F1N4M7 1 61 
Uncharacterised protein (armadillo repeat gene 
deleted in velocardiofacial syndrome (ARVCF)) 
E1BPV1 2 59 
Uncharacterised protein (NEK10-
Uncharacterised protein; NIMA-related kinase 
10) 
E1BHZ1 2 58 
Keratin associated protein 13-1 A1A4M9 2 57 
Uncharacterised protein (uncharacterised) F1MSF0 2 57 
Histone H4 E1B9M9 1 56 
Gamma-glutamylcyclotransferase Q32LE4 1 55 
Uncharacterised protein (JAKMIP2 - Janus 
kinase and microtubule interacting protein 2) 
G5E551 2 54 
TOX high mobility group box family member 4 Q0P5K4 1 53 
Uncharacterised protein (TBC1D32 - TBC1 
domain family, member 32) 
F1N7V1 2 51 
Proteasome subunit alpha type-6 Q2YDE4 1 50 
Uncharacterised protein (KIAA1009 ortholog) F1MZ01 2 50 
Uncharacterised protein (MYO5B - Myosin VB) F1MMQ6 2 50 
Uncharacterised protein (Phospholipid 
phosphatase related 4) 
F1MJ26 2 49 
Uncharacterised protein (MGA - MGA, MAX 
dimerization protein) 
E1BKB7 2 49 
Uncharacterised protein (GOLGB1 - Golgin B1) E1BKZ5 2 47 
Histone H3 E1BGN3 1 46 
Uncharacterised protein (CROCC - Ciliary 
rootlet coiled-coil, rootletin) 
E1BBS9 3 46 
Protein FAM149B1 A0JNF3 2 45 
Alpha-enolase F1MB08 2 45 
Uncharacterised protein (UBR4 - Ubiquitin 
protein ligase E3 component n-recognin 4) 
E1BHT5 3 45 
Complement component C9 Q3MHN2 1 44 
Uncharacterised protein (DOCK8 - Bos taurus 
dedicator of cytokinesis 8 (DOCK8)) 
E1BNA6 2 44 
Uncharacterised protein (KPRP - Keratinocyte 
proline-rich protein) 
E1BLN6 1 44 
Uncharacterised protein (CCDC14 - Coiled-coil 
domain containing 14) 
F1MS02 2 43 
Uncharacterised protein (Strawberry notch 
homolog 1(Drosophila)) 
E1BMP8 3 42 
DNA-directed RNA polymerase subunit beta A5PJW8 1 42 
Uncharacterised protein (CRYGN-Crystallin, 
gamma N) 
E1BDQ1 1 42 
Flotillin-1 Q08DN8 1 41 
Int. J. Mol. Sci. 2019, 21, 2861  11 of 41 
 
Uncharacterised protein (SMG6—
Uncharacterised protein; Bos taurus smg-6 
homolog, nonsense mediated mRNA decay 
factor (C. elegans) (SMG6)) 
E1BFK4 2 41 
C1QTNF3 protein A7MB82 1 41 
Uncharacterised protein (Protocadherin gamma 
subfamily B, 1) 
F1MCA2 1 40 
Uncharacterised protein (Death-associated 
protein kinase 1) 
F1MRL0 1 39 
Acyl-coenzyme A thioesterase THEM4 A1A4L1 1 37 
Uncharacterised protein (Centrosomal protein 
104kDa) 
E1BND2 1 37 
C8G protein A8YXZ2 1 36 
Uncharacterised protein (SERPINB12—Serpin 
family B member 12) 
E1BDF5 1 36 
Uncharacterised protein (SLAMF9 SLAM family 
member 9) 
E1BNF9 1 36 
Complement C1s subcomponent Q0VCX1 1 36 
Uncharacterised protein (methyltransferase like 
3 (METTL3)) 
F1MX80 1 35 
Uncharacterised protein (SPAG9—Sperm 
associated antigen 9) 
F1MZ69 1 35 
Adenosylhomocysteinase Q3MHL4 1 35 
Uncharacterised protein (HIVEP3—Human 
immunodeficiency virus type I enhancer binding 
protein 3) 
F1MBK6 1 34 
Coagulation factor V F1N0I3 1 33 
Uncharacterised protein (VPREB1—
Uncharacterised protein) 
F1N160 1 33 
Uncharacterised protein (SERPING1) E1BMJ0 1 33 
PPARD protein A4IFL4  32 
Uncharacterised protein F1MZ93 1 32 
Uncharacterised protein (NCBP1—Nuclear cap 
binding protein subunit 1) 
E1BMM0 1 32 
Transthyretin O46375 1 32 
Uncharacterised protein (Cryptochrome-1) F1MXB2 1 32 
Tubulin alpha chain F1MNF8 1 31 
1 Ions score is −10*Log(P), where P is the probability that the observed match is a random event. 
Individual ions scores > 31 indicated identity or extensive homology (p < 0.05). Protein scores were 
derived from ions scores as a non-probabilistic basis for ranking protein hits. 
The Venn diagram in Figure 3 represents common and specific deimination hits in serum and 
serum-EVs. Overall 87 deiminated protein hits were common to serum and serum-EVs, while 31 hits 
were identified to be deiminated in serum only and 90 hits were identified to be deiminated in EVs 
only (Figure 3A). Following KEGG pathway analysis for these deiminated protein hits, a number of 
common KEGG pathways enriched in deiminated proteins were identified in serum and serum EVs, 
while differences were observed in KEGG pathways relating to infection, immunity, disease and 
metabolism, that were specific to serum or serum-EVs only, respectively (Figure 3B).  
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Figure 3. Deiminated proteins identified in bovine serum and serum-EVs. (A) Species specific hits 
identified for deiminated proteins in bovine serum (Table 1) and serum-EVs (Table 2) respectively, as 
well as number of overlapping hits are presented. (B) KEGG (Kyoto Encyclopedia of Genes and 
Genomes) pathways identified to be enriched in deiminated proteins in bovine serum and serum-EVs 
respectively, as well as number of overlapping KEGG pathways, are presented. For specific KEGG 
pathways presented in the Venn diagram, see the protein–protein interaction networks in Figures 4–
8. 
3.3. Protein–Protein Interaction Network Identification of Deiminated Proteins in Bovine Serum and Serum-
EVs 
For the prediction of protein–protein interaction networks of the deimination candidate 
proteins, the protein ID lists for serum and serum-EVs respectively, were submitted to STRING 
(Search Tool for the Retrieval of Interacting Genes/Proteins) analysis (https://string-db.org/) and 
analyzed for KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways (Figure 3B and Figures 
4–8). Protein interaction networks were based on known and predicted interactions and represent all 
deiminated proteins identified in serum (Figure 4), all deiminated proteins identified in EVs (Figure 
5) as well as deiminated proteins identified in serum only (Figure 6) or in EVs only (Figure 7), or 
common deimination candidates in EVs and serum (Figure 8). The PPI enrichment p-value for all 
deiminated proteins identified in bovine serum (based on protein identifier sequences) was found to 
be p < 1.0 × 10−16 and for all deiminated proteins identified in the serum-derived EVs, the PPI 
enrichment p-value was also found to be p < 1.0 × 10−16 (Figure 4 and Figure 5). For deiminated 
proteins identified in serum only (but not EVs) the PPI enrichment p-value was also p < 1.0 × 10−16 
(Figure 6), while for deiminated proteins identified specifically in EVs, the PPI enrichment p-value 
was p = 4.83 × 10−8 (Figure 7). For common proteins found deiminated in serum and in serum-EVs, 
the PPI enrichment p-value was p < 1.0 × 10−16 (Figure 8). This indicates that in all cases, the identified 
protein networks have significantly more interactions than what would be expected for a random set 
of proteins of similar size, based on information drawn from the genome.  
The KEEG pathways related to all deiminated proteins identified as deiminated in whole serum 
are shown in Figures 4A–E. For KEGG pathways relating to infection these belonged to: 
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“Complement and coagulation cascades”, “S. aureus infection”, “systemic lupus erythematous”, 
“prion diseases”, “pertussis”, “trypanosomiasis”, “amoebiasis”, “leishmaniosis”, “tuberculosis”, 
“Epstein–Barr virus infection” (Figure 4B); For KEGG pathways relating to immunity these related 
to: “phagosome”, “primary immunodeficiency”, “FC-gamma R-mediated phagocytosis”, “intestinal 
immune network for IgA production”, “allograft rejection”, “Fc epsilon RI signalling pathway”, 
“autoimmune thyroid disease”, “B-cell receptor signalling pathway”, “rheumatoid arthritis”, 
“ferroptosis” (Figure 4C); For KEGG pathways relating to cancer and disease these related to: 
“transcription misregulation in cancer”, “bladder cancer”, “viral myocarditis”, “Rap1 signalling 
pathway”, “natural killer cell mediated cytotoxicity”, “measles”, “dilated cardiomyopathy”, 
“asthma” (Figure 4D); For KEGG metabolic pathways these related to: “phospholipidase D signalling 
pathway”; “ECM-receptor interaction”; “vitamin digestion and absorpition”, “calcium signalling 
pathway”, “fat digestion and absorption”, “NF-kappa B signalling pathway”, “cholesterol 
catabolism”, “hematopoietic cell lineage”, “PI3K-Akt signalling pathway” and “platelet 
activation”(Figure 4E). 
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Figure 4. Protein–protein interaction networks show all deiminated proteins which were identified in 
bovine serum. Protein–protein interactions were reconstructed based on both known and predicted 
interactions in serum of Bos taurus, using STRING analysis. (A) Query proteins are indicated by the 
coloured nodes represent and first shell of interactors. (B) KEGG pathways relating to the identified 
proteins and reported in STRING and relating to infection are highlighted (see colour code included 
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in the figure). C. KEGG pathways relating to the identified proteins and reported in STRING are 
highlighted for immunity (see colour code included in the figure). D. KEGG pathways relating to 
cancer and disease for deiminated proteins identified are highlighted (see colour code included in the 
figure). E. KEEG pathways relating to metabolism for deiminated proteins identified are highlighted 
(see the colour code included in the figure). The coloured lines highlight which protein interactions 
are identified through known interactions (this refers to curated databases, experimentally 
determined), through predicted interactions (this refers to gene neighborhood, gene fusion, gene co-
occurrence) or through co-expression, text mining or protein homology (the colour key for connective 
lines is included in the figure). 
The KEEG pathways related to deiminated proteins identified as deiminated in whole serum 
only are shown in Figure 5 (A,B). These were: “complement and coagulation cascades”, 
“phagosome”, “Rap1 signalling pathway” and “bladder cancer”. 
 
Figure 5. Protein–protein interaction networks of deiminated protein candidates identified in bovine 
serum only (not identified in EVs). Protein–protein interactions were reconstructed based on both 
known and predicted interactions by STRING analysis. (A) Query proteins are indicated by the 
coloured nodes and represent the first shell of interactors. (B) KEGG pathways reported in STRING 
and related to the identified proteins are highlighted (see the colour code included in the figure). The 
coloured lines highlight which protein interactions are identified through known interactions (this 
refers to curated databases, experimentally determined), through predicted interactions (this refers to 
gene neighborhood, gene fusion, gene co-occurrence) or through co-expression, text mining or protein 
homology (the colour key for connective lines is included in the figure). 
The KEEG pathways related to all deiminated proteins identified in EVs are shown in Figures 
6A-C. For KEGG pathways relating to infection these belonged to: “complement and coagulation 
cascades”, “S. aureus infection”, “systemic lupus erythematous”, “pertussis”, “prion diseases”, 
“amoebiasis”, “trypanosomiasis”, “leishmaniosis” (Figure 6B); Other KEGG pathways identified 
were: “oestrogen signalling pathway”, “phagosome” “vitamin digestion and absorption”, “asthma”, 
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“primary immunodeficiency”, “Fc gamma R-mediated phagocytosis”, “ferroptosis”, “ fat digestion 
and absorption”, “cholesterol metabolism”, “HIF-1 signalling pathway”. 
 
 
Figure 6. Protein–protein interaction networks of all deiminated proteins identified in serum-EVs of 
Bos taurus. Protein–protein interactions were reconstructed based on both known and predicted 
interactions by STRING analysis. (A) Query proteins are indicated by the coloured nodes and 
represent the first shell of interactors. (B) KEGG pathways reported in STRING and relating to 
infection are highlighted (see colour code included in the figure). (C) KEGG pathways relating to the 
identified proteins and reported in STRING are highlighted for other pathways (see colour code 
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included in the figure). The coloured lines highlight which protein interactions are identified through 
known interactions (this refers to curated databases, experimentally determined), through predicted 
interactions (this refers to gene neighborhood, gene fusion, gene co-occurrence) or through co-
expression, text mining or protein homology (the colour key for connective lines is included in the 
figure). 
The KEEG pathways related to deiminated proteins identified as deiminated in EVs only are 
shown in Figure 7 (A,B). These were: “oestrogen signalling pathway”, “S. aureus infection”, 
“complement and coagulation cascades”, “biosynthesis of amino acids”. 
 
Figure 7. Protein–protein interaction networks of deiminated protein candidates identified in bovine 
serum-EVs only (not identified in total serum). Protein–protein interactions were reconstructed based 
on both known and predicted interactions by STRING analysis. (A) Query proteins are indicated by 
the coloured nodes and represent the first shell of interactors. (B) KEEG pathways relating to the 
identified deiminated proteins and reported in STRING are highlighted (see colour code included in 
the figure). The coloured lines highlight which protein interactions are identified through known 
interactions (this refers to curated databases, experimentally determined), through predicted 
interactions (this refers to gene neighborhood, gene fusion, gene co-occurrence) or through co-
expression, text mining or protein homology (the colour key for connective lines is included in the 
figure). 
Deiminated proteins that were common to serum and serum-EVs were furthermore analyzed 
for KEGG pathways (Figure 8A–E). Pathways identified for infection were: “complement and 
coagulation cascades”, “S. aureus infection”, “systemic lupus erythematous”, “pertussis”, “prion 
diseases”, “amoebiasis”, “trypanosomiasis”, “leishmaniosis”, “tuberculosis”, “malaria” (Figure 8B); 
KEGG pathways for immunity (and diseases) were: “Fc gamma R-mediated phagocytosis”, “primary 
immunodeficiency”, “Fc epsilon RI signalling pathway”, “intestinal immune network for IgA 
production”, “autoimmune thyroid disease”, “allograft rejection”, B-cell receptor signalling 
pathway”, “phagosome”, ”viral myocarditis”, rheumatoid arthritis (Figure 8C); KEGG pathways for 
cancer and disease were: “natural killer cell mediated cytotoxicity”, “dilated cardiomyopathy 
(DCM)”, “viral myocarditis”, “asthma”, “measles” (Figure 8D); KEGG metabolic pathways for 
common deiminated proteins in serum and serum-EVs were: “Vitamin digestion and absorption”, 
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“ferroptosis”, “fat digestion and absorption”, “cholesterol metabolism”, “mineral absorption”, 
“phospholipase D signalling pathway”, PI3K-Akt signalling pathway”, NF-kappa B signalling 
pathway”, “hematopoietic cell lineage” and “platelet activation” (Figure 8E). 
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Figure 8. Protein–protein interaction networks for common deiminated protein candidates identified 
in bovine serum and serum-EVs (excluding serum-specific or EV specific candidates). Protein–protein 
interactions were reconstructed based on both known and predicted interactions by STRING analysis. 
(A) Query proteins are indicated by the coloured nodes and represent the first shell of interactors. (B) 
KEGG pathways for to the identified deiminated proteins and reported in STRING and relating to 
infection are highlighted (see colour code included in the figure). (C) KEGG pathways relating to the 
identified proteins and reported in STRING are highlighted for immunity (see colour code included 
in the figure). (D) KEGG pathways relating to cancer and disease for deiminated proteins identified 
are highlighted for (see colour code included in the figure). (E) KEEG pathways relating to 
metabolism for deiminated proteins identified are highlighted (see colour code included in the 
figure). The coloured lines highlight which protein interactions are identified through known 
interactions (this refers to curated databases, experimentally determined), through predicted 
interactions (this refers to gene neighborhood, gene fusion, gene co-occurrence) or through co-
expression, text mining or protein homology (the colour key for connective lines is included in the 
figure). 
3. Discussion 
The current study is the first to profile deiminated protein signatures in serum and serum-EVs 
of cattle, using Bos taurus as a model species. F95-enrichment for deiminated proteins from serum 
and serum-EVs revealed a range of immunological, metabolic and gene regulatory proteins as 
candidates for this post-translational modification, therefore indicating hitherto under-recognized 
modes for protein-moonlighting of these proteins in bovine immunity and physiology. Few studies 
have hitherto assessed roles for PADs and deimination in cattle [22,23,42], while a range of studies 
have been carried out on EVs in relation to cattle immunity, fertility and development 
[54,57,60,61,63,65,68,74,78,83,85,88,90]. Export of post-translationally modified proteins, such as 
deiminated proteins in the current study, has not been assessed before in cattle serum.  
PAD proteins were assessed in bovine serum via cross-reaction to antibodies raised against 
human PAD2, PAD3 and PAD4 isozymes, with the strongest cross-reaction found with anti-human 
PAD4 at a predicted size of 70–75 kDa for PAD proteins. Protein sequence alignment of cow and 
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human PADs showed that the individual isozymes clustered together between the two species, 
therefore the lack of cross-reaction with anti-human PAD2 and PAD3 antibodies may possibly be 
explained by differences in folding of the PADs, but will remain to be further investigated. It must 
be noted that neither anti-human PAD1 nor PAD6 antibodies were tested against bovine sera in the 
current study. The anti-human antibodies have previously been shown to cross-react with PADs from 
diverse taxa, with PAD2, which is considered the phylogenetically most conserved isoform, 
predominantly cross-reacting best with other species, including bony and cartilaginous fish, birds, 
mole-rat, alligator, camelids, cetaceans and pinnipeds [15–17,92,93,96–99].  
A number of bovine species-specific deiminated protein candidates were identified in both 
serum and serum-EVs, using F95-enrichment in tandem with LC-MS/MS analysis. This analysis 
revealed some key metabolic and immune related proteins, with 87 characterised common 
deiminated proteins in serum and EVs, while 31 characterised deiminated protein hits were specific 
for serum and 90 characterised deiminated protein hits were specific for serum-EVs. Overall, the hit 
for deiminated proteins was higher in the serum-EVs, with a total hit of 179, compared to 118 in 
serum. Upon assessment of protein–protein interaction networks using STRING analysis, the PPI 
enrichment p-value for all deiminated proteins identified in bovine serum and serum-EVs, as well as 
for deiminated proteins identified either in serum or EVs only, indicated that the identified protein 
networks have significantly more interactions than expected for a random set of proteins of similar 
size, drawn from the genome, and that the proteins are at least partially biologically connected, as a 
group (Figures 4–8). When assessing KEGG pathways for deiminated proteins relating to infection 
and immunity, diseases and metabolism, a number of pathways overlapped between serum and 
serum-EVs, while KEGG pathways only found in EVs related to HIF-1 signalling, oestrogen 
signalling and biosynthesis of amino acids. KEGG pathways specific for serum only related to 
Epstein–Barr virus infection, transcription misregulation in cancer, bladder cancer, Rap1 signalling 
pathway, calcium signalling pathway, ECM-receptor interaction. This indicates differences in cell-
communication via export of deiminated proteins in serum-EVs (Figure 3B). 
KEGG pathways in common with both serum and serum-EVs related to a number of 
immunological pathways including the complement and coagulation cascade, bacterial infection, 
parasitic infection and importantly viral infections, as well as viral myocarditis. The role for 
deimination of immunoglobulins may be of considerable importance, particularly in relation to 
enveloped viruses as identified in the current study via deiminated KEGG pathways highlighted for 
Epstein–Barr virus in cow serum. Deimination in this KEGG pathway has also recently been 
identified in aggressive glioblastoma cells [100], and the relationship between viral infection cancers 
still remains to be fully understood [101,102]. In the cow, a link between viral infections and cancer 
has also been made [103–105]. Furthermore, oncolytic viruses from cow, such as bovine herpesvirus 
type 1, have been considered for application as a human broad spectrum cancer therapeutic [106]. 
The cow is known for its unusual immune responses and is a model organism for studying 
neutralizing antibodies against viral infections, including HIV [3–5]. Understanding of immune 
responses against enveloped viruses is of pivotal importance as indeed coronaviruses (CoVs) 
including severe acute respiratory syndrome (SARS) and COVID-19, also fall under enveloped 
viruses. CoVs are enveloped, positive-stranded RNA viruses with a nucleocapsid, and the structure 
of the envelope has a crucial role in virus pathogenicity as it promotes viral assembly and release 
[107]. While a range of studies has focused on modelling the envelope proteins, post-translational 
deimination has not yet been investigated in relation to SARS and CoVs, while it has been previously 
identified to play roles in rhinovirus infection [41]. Therefore, the roles for post-translational 
modifications via deimination may play some roles in structural interactions with the virus, 
particularly as cow immunoglobulins were here identified as deimination candidates, both in serum 
as well as in serum-EVs, and cow antibodies with an extended knob structure formed from the third 
complementarity determining region of the heavy chain are known to bind bovine and human 
pathogens and be capable of remarkably broad viral neutralization [3–5,108]. Post-translational 
deimination of cow Ig’s, which are reported in the current study for the first time, have yet to be 
further explored. Roles for PADs in anti-viral responses have previously been identified via the 
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generation of NETosis [37], which can be PAD-mediated and is also a recognized mechanism in anti-
pathogenic functions in cattle [109]. Deimination has also been identified to modulate chemokines in 
anti-HIV responses [40] and higher levels of anti-cyclic citrullinated peptide antibodies have been 
found sera of HIV patients [110]. Higher amounts of cyclic citrullinated peptides in sera have indeed 
been related to infectious diseases including a number of viral, bacterial and parasitic infections [111]. 
The ability of PAD homologues in bacteria, for example bacterial arginine deiminase in Mycoplasma 
arginini, a Gram-negative bacterium, has furthermore been shown to act as an effective anti-viral 
agent against HIV [112]. Interestingly, a recent comparison of transcriptomics data between healthy 
and SARS-CoV-2 infected patients’ lung biopsies 
(https://www.ncbi.nlm.nih.gov/bioproject/PRJNA615032), reveals a 6-fold downregulation of PAD4 
mRNA level, assessing 17 SARS-CoV-2 versus 106 healthy individuals. This highlights importance 
for PADs in virus host-pathogen interactions, including in COVID-19. Only PAD4 was reported in 
this COVID-19 patient cohort. Importantly, as PAD4 is involved in gene regulation and also 
considered one key-driver of NETosis [37], reduced PAD4 levels, observed in these COVID-19 
patients, may contribute to less defences against viral infection due to gene regulatory changes, 
changes in deimination of immune related proteins, or impaired NETosis in these individuals. 
Whether the virus manipulates PAD4 expression, as an immune evasion mechanism, or whether 
individuals with lower PAD4 are more prone to SARS-CoV-2 infection, remains to be further 
investigated. Myocarditis is furthermore one of the hallmarks of COVID-19 [113] and roles for 
deimination/citrullination have previously been identified in a murine model of coxsackievirus B3-
induced viral myocarditis [114]. As viral myocarditis was here identified as a KEGG pathway for 
deiminated proteins in cow sera and serum-EVs, to what extent PADs and deimination could be 
involved in viral induced myocarditis, including in relation to COVID-19, may be of considerable 
interest and remains to be further investigated.  
The complement and coagulation cascades were identified as a common KEGG immune 
pathway enriched in deiminated proteins in cow serum and serum-EVs. The complement system 
bridges innate and adaptive immunity, has roles in clearing apoptotic and necrotic cells and is in the 
front line for clearing invading pathogens [115–119]. Dysregulation of the complement system is 
furthermore associated with a range of pathologies [120]. In the current study a range of proteins 
from the complement cascade were identified as deiminated in cow serum and serum EVs, with 
complement components identified both in serum and serum-EVs including C1q, C3, C4A, C5a, C7, 
C8, C9 factor B, Factor H, C4-binding protein; while complement components found deiminated only 
in whole serum were C6, clusterin, and collectin-43 (CL43). C3 is the central component of the 
complement cascade and has furthermore been implicated in tissue remodeling during teleost 
ontogeny [121–124] as well as in regeneration [125]. A range of complement proteins have recently 
been identified by our group to be deiminated in a range of taxa throughout the phylogenetic tree 
including teleost and cartilaginous fish, camelids, cetaceans, pinnipeds, camelids and peglagic 
seabirds [16,17,91–96,98,99]. The bovine complement system [126] has been widely studied, including 
in immune defences against bovine anaplasmosis [127], in relation to heat-stress in dairy cows [128], 
susceptibility to bacterial infection relating to copper-deficiency [129]. Roles for modulation of 
complement regulation in relation to poxviral and pestiviral infections have been identified [130–
132], including immune evasion by bovine herpesvirus 1 (BHV-1) [133], while and roles for antibody-
dependent complement-mediated killing of mycoplasma have recently been revealed [134]. The 
finding of deiminated complement components highlight hitherto understudied roles for post-
translational deimination in the known diversity of complement function throughout phylogeny 
[135–139]. Furthermore, immune evasion of bacteria (Gingivalis) by deimination of the host’s C5a has 
previously been identified [20] and indeed C5a was here identified as a deimination candidate in cow 
serum. Our findings suggest that protein deimination may play hitherto unidentified roles in the 
known unusual anti-pathogenic functions of cow serum, including via EV-transport, also 
contributing to complement function in homeostatic processes.  
Alpha-2-macroglobulin was found to be deiminated in cow serum and serum-EVs. It forms part 
of the innate immune system and clears active proteases from tissue fluids [140]. In cow plasma-EVs, 
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alpha-2-macroglobulin has been identified [55], but the current study is the first report of deiminated 
bovine alpha-2-macroglobulin. Alpha-2-macroglobulin is related to the other thioester-containing 
proteins, complement proteins C3, C4 and C5, and is a phylogenetically conserved protein from 
arthropods to mammals [115,141,142]. The deimination of alpha-2-macroglobulin has recently been 
identified by our group in teleost fish, camelid, alligator and birds [15,92,93,99]. In the cow, alpha-2-
macroglobulin has been widely studied and has amongst other binding affinities to TGF-beta and a 
range of cytokines [143] While alpha-2-macroglobulin is a known glycoprotein, less is known about 
deimination and such post-translational modification may facilitate protein moonlighting contribute 
both to its conserved immunological, as well as multifaceted functions in a range of taxa. 
Serotransferrin was identified as a major deimination candidate in the current study both in cow 
serum and serum-EVs. It is an iron-binding protein with multifaceted functions in development and 
immunity [144,145]. Serotransferrin is found both in plasma and mucosal tissue and has important 
roles in anti-pathogenic responses across phylogeny, including in cattle, by withdrawing iron from 
pathogens including bacteria, fungi and viruses [146–149]. Furthermore, some viruses, including 
zoonitic ones, have been identified to utilize human transferrin receptor for viral entry and infection 
[150,151]. In chronic disease, for example lung diseases, the dysregulation of iron homeostasis can 
facilitate viral respiratory infections and secondary bacterial infections [152]. Deimination of 
serotransferrin has previously been identified by our group in teleost serum and mucosa [15,16]. 
Therefore, its deimination identified here in cow indicates that serotransferrin is deiminated in 
several taxa and this may be of considerable importance in its immune responses to a range of 
pathogens throughout phylogeny, as well as with respect to a range of human diseases and infections. 
Intestinal immune network for IgA production was identified as deiminated for proteins 
common in serum and serum-EVs. The gut associated lymphoid system in the intestinal mucosa 
produces the highest level of antibody-secreting (IgA) plasma cells in the body [153,154]. It has been 
established that IgA cells play roles beyond antibody production, including having monocytic 
potential and antimicrobial properties via rapid secretion of cytokines as well as acting as regulators 
of inflammation [153]. IgA production in the gut mucosa plays major roles in maintaining the 
integrity of the mucosa and is therefore imperative for the host’s homeostasis and survival [154]. IgA 
is also produced in the BALT of the respiratory mucosal system [154] and is therefore important in 
defences against respiratory infections, including viral infections and this has also been identified in 
cattle bovine respiratory syncytial virus [155]. Deimination has been related to mucosal immunity in 
teleost fish, including in response to bacterial immune challenge and in EVs mediated mucosal 
immunity [15,16]. Roles for deimination in the regulation of intestinal immune networks for IgA 
production identified here may be of considerable interest and remain to be further investigated. 
Various immunoglobulin (Ig) proteins and Ig superfamily members were identified here to be 
deiminated in cow serum and serum-EVs, confirming that Ig’s can be exported via EVs. Ig’s identified 
both in serum and serum-EVs were immunoglobulin lambda-like and immunoglobulin heavy chain 
constant mu. Ig’s identified in addition as deiminated in serum only, were the immunoglobulin J 
(joining) chain responsible for dimeric IgA and pentameric IgM and the polymeric immunoglobulin 
receptor (pIgR) that facilitates IgA’s translocation from the lamina propria through intestinal 
epithelia to the lumen. This is the first report of deiminated Ig’s in bovine serum and serum-EVs. 
Previous studies have identified that cow plasma EVs contain immunoglobulin J chain [55], but this 
did not come up as a deimination candidate in EVs, only in whole serum in the current study, and 
therefore may not be exported in EVs in the deiminated form. We have previously confirmed post-
translational deimination if Ig’s in several other taxa, including shark, camelid, alligator and birds 
[17,92,93,99], as well as in teleost fish [15,16], and furthermore reported EV-mediated transport of Ig’s 
in shark and camelid [17,92]. Ig’s are key molecules in adaptive immunity and studied in diverse 
taxa. Post-translational deimination of Ig’s and roles in Ig functions remain to be further investigated 
but have been related to the IgG Fc region in bronchiectasis and RA [156]. Current understanding of 
Ig diversity throughout the phylogenetic tree is still incomplete [157–162]. Therefore, our 
identification of deimination of Ig’s in diverse taxa, including in bovine Ig’s in the current study, 
highlights a novel phylogenetically conserved concept of the diversification of Ig’s via this post-
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translational change. Our reported findings may furthermore shed some light on the unusual 
immune responses in bovine sera, relating to their immunoglobulins. 
Serpins (serine proteases) were identified both in serum and serum-EVs, with both common 
candidates in serum and EVs as well as some specific serpin targets deiminated in serum or EVs. 
Serpins have multifaceted roles, ranging from protease inhibition to transport of hormones as well as 
regulation of chromatin organization [163]. Anti-viral roles for serine proteases have been identified 
in the airway, and serine proteases have been identified as drug targets for respiratory diseases, 
including virus infections [164,165]. Bovine serpins are cross-class inhibitors and shown to be 
strongly active against trypsin, as well as regulating caspases, therefore playing important roles in 
control of apoptosis in mammals [166]. In cow, serine proteases are for example involved in defences 
against Babesia bovis, a tick-borne and major apicomplexan pathogen in the cattle industry worldwide 
[167]. Serpins are identified in a range of taxa and for example serpin based peptides from alligator 
have been assessed as antimicrobials against multi-drug resistant pathogens [168]. Interestingly, 
serpins have been identified to be deiminated in alligator, and furthermore in humans, where 
deimination has been related to the modulation of protease activity and downstream effects on 
serpin-regulated pathways in rheumatoid arthritis [169]. As deimination of serpin pathways seems 
therefore a conserved phenomenon in a range of taxa, including in cattle as observed here, such post-
translational regulation via deimination may contribute to its various functions, relating to immunity 
and anti-pathogenic defences, as well as also autoimmune diseases, and this remains to be further 
investigated.  
Fat digestion and absorption was identified as a KEGG pathway in both cow serum and serum-
EVs alongside adiponectin as a specific target. The adipocytokine signalling pathway has key 
regulatory roles in metabolism and glucose regulation [170–173] and is linked to a range of 
pathologies, including type II diabetes and insulin resistance [174], to myopathies [175] and cancer 
[176]. Adiponectin has also been linked to longevity [177] and to regenerative functions [178]. In the 
cow, adiponectin is a known glycoprotein and has been assessed in bovine tissues as well as body 
fluids [179] and amongst other been identified as a pro-survival signal in ER stress in the mammary 
gland [180]. Adiponectin has recently been identified as a deimination candidate in several taxa with 
unusual metabolism, including camelids, the naked mole-rat, orca and alligator [92,93,96,98]. A range 
of apolipoproteins was furthermore identified to be deiminated in the current study in cow serum 
and serum-EVs. In cattle, apolipoprotein B-100, apolipoprotein A-I and apolipoprotein C-III have 
previously been identified as biomarkers for fatty liver and related diseases [181]. In other taxa, 
apolipoproteins have also been found to display antimicrobial activity against a range of pathogenic 
bacteria [182–185] as well as against viral (HIV) replication [186]. Various apolipoproteins have 
recently been identified as deimination protein candidates by our group in several taxa 
[15,16,92,93,99]. The deimination of apolipoproteins therefore needs further investigation in relation 
to their multifaceted phylogenic immune and metabolic functions. 
Selenoprotein P (Sepp1) was identified to be deiminated in whole serum and serum-EVs. It is a 
plasma glycoprotein, mainly secreted from liver but also other tissues and contains most of the 
selenium in mammalian plasma [187–189]. In the cow roles for selenoproteins in mammary gland 
physiology and in milk formation have been identified [190] and roles for responses to oxidative 
stress in bovine arterial endothelial cells have also been suggested [191]. It has antioxidant properties 
[188] and serves in homeostasis and distribution of selenium [189]. Roles for selenoproteins in the 
regulation of the contraction and relaxation of bronchiolar smooth muscle have furthermore been 
identified [192]. Sepp1 is known to be glycosylated, and recently it has been identified as a 
deimination candidate in cetaceans, pinnipeds and alligators [93,96,97]. The contribution of 
deimination in the functional diversity and conserved functions of Sepp1 throughout phylogeny will 
remain to be further investigated. 
KEGG pathways for ECM-receptor interactions were identified to be enriched in deiminated 
proteins in whole cow serum only. ECM-receptor interactions play both direct and indirect roles in 
controlling multifaceted cellular activities, such as cell differentiation, migration and proliferation as 
well as cell adhesion and apoptosis [193]. ECM-receptor interaction KEGG pathways have been 
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identified in cancer [193] and enrichment for this pathway has been reported mesenchymal stem cell 
EVs [194]. Regulation of ECM-receptor interactions via post-translational deimination has recently 
been identified by our group via enrichment of deiminated proteins in KEGG pathways for ECM-
receptor interactions in the fin whale, a long-lived cancer-resistant animal [96], in the alligator, an 
animal with unusual antibacterial and anti-viral responses [93], in the wandering albatross (Diomedea 
exulans), also an unusually long-lived bird for an avian species [99], as well as in aggressive brain 
cancer cells [100]. In the cow, ECM-receptor interactions are amongst other related to depot-specific 
adipogenesis [195] and found to be over-represented in specific cattle breeds [196]. ECM-receptor 
interaction pathway has furthermore been identified in Holstein cattle in relation to adaptive immune 
responses following viral vaccination [197] and in intra-mammary infection with Streptococcus 
agalactiae [198]. Therefore, deimination in this pathway may be of significant importance in anti-
bacterial and anti-viral responses. Deimination in ECM-receptor interaction pathway is here 
described for the first time in cow and may play roles in the multifaceted functions of this pathway.  
KEGG pathways for calcium signalling pathway were here identified to be enriched in 
deiminated proteins in whole bovine serum only. Calcium is a key modulator in a range of 
immunological, metabolic and developmental functions [199–202]. Calcium signalling is linked to a 
wide range of physiological and pathological processes [203–205], is a key driver for post-
translational deimination [206–208] and plays an important role in the regulation of EVs [11,48]. In 
cattle, calcium is linked to many immunological pathways including inflammatory diseases [209], 
virus replication [210], parasitic infection [211], wound healing [212], reproduction [213,214] and 
adrenal function [215]. Interestingly, calcium regulation has been shown to differ between Holstein 
and Jersey cows, including via serotonergic stimulation of the calcium pathway [216]. The 
identification in the current study of enrichment in deiminated proteins in the calcium signalling 
pathway in cow serum indicates a regulatory function in multiple key pathways of physiological and 
pathological processes via this post-translational modification.  
RAP1 (Ras-related protein 1) signalling pathway was identified as enriched in deiminated 
proteins in whole bovine serum. It belongs to a superfamily of small GTPases, with pleiotrophic 
regulatory functions in cellular processes, such as nuclear transport, cell cycle progression, vesicle 
trafficking, cell adhesion and cytoskeletal rearrangement [217]. Rap1 is an inflammatory regulator, is 
highly expressed in platelets and is a key molecule for platelet activation and adhesion in injury 
[218,219]. In mammals, Rap1 is a phylogenetically conserved telomere-interacting protein and 
promotes endothelial barrier function and angiogenesis [220,221], as well as being involved in cancer 
cell invasion and metastasis [222]. Rap1 also has roles in oxidative stress and metabolism, and besides 
cancer it is linked to metabolic and cardiac disorders, including cardiomyopathy [217] as well as 
Kabuki syndrome (characterised by congenital anomalities and developmental delay) [223]. Rap1 has 
also been linked to bone growth, including in bovine chondrocyte models [224]. Rap1 has been 
identified to undergo post-translational modifications by phosphorylation, geranylgeranylation or 
guanine nucleotide exchange factors [225], but deimination in this pathway has not been identified 
before, to our knowledge. To what extent deimination contributes to the multifaceted functions of 
Rap1 signalling in health and disease may therefore be of considerable interest. 
Transcription misregulation in cancer and bladder cancer KEGG pathways were identified as 
enriched in deiminated proteins in bovine serum. Cows belong to a group of long-lived mammals 
that display cancer resistance and are considered a translationally valuable model for human cancers 
[2], including for breast cancer as they have been reported to be resistant to mammary cancer [226]. 
Cattle do generate bladder tumors and these have been studied in relation to various molecular 
mechanisms as well as in relation to viral infections, including papilloma and leukemia viruses, also 
in a comparative context to human cancer [103,227–229]. Bovine leukemia virus has furthermore been 
linked to telomerase upregulation and tumor induction in cattle [230]. PADs and deimination have 
been widely studied in a range of cancers, including via epigenetic regulation [9–11,100,231–234] but 
this is the first identification of post-translational regulation of such pathways via deimination in 
cattle. 
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HIF-1 (hypoxia inducible factor) signalling KEGG pathways were enriched in deiminated 
proteins in serum-EVs only. HIF-1 regulates oxygen homeostasis and is the key factor mediating the 
mammalian hypoxic response [235]. HIF-1 has roles in inflammation, cancer, angiogenesis and 
cardiovascular disease [236,237]. Furthermore, roles for HIF have been identified in bacterial 
infections [235] and a link between pathogenic agents and cancer has been identified, as viruses, 
bacteria and parasites may deregulate HIF-1 signalling associated cancer cells [238]. In cows, HIF-1 
has for example been found to play roles in immune responses against Theileria annulata, a protozoan 
parasite of major economically importance for the cattle industry [239]. HIF-1 has also been identified 
to be important in angiogenesis and the maintenance of capillary structures for final follicle 
maturation in the cow ovary [240]. Furthermore, HIF-1 has recently been identified as a genomic 
marker differing between cattle breeds, including highland-adapted cattle [241]. Interestingly, 
enrichment in deiminated proteins in KEGG HIF-1 signalling pathways has previously been 
identified in EVs only, in some species with unusual immune and metabolic function including the 
naked mole-rat and deep-diving whales, both of which are animal models of hypoxia-tolerance and 
cancer-resistance [96,98]. Furthermore, deimination of HIF-1 regulation were recently identified in 
aggressive brain cancer (glioblastoma) cells [100]. To what extent deimination regulates HIF-1 
signalling in relation to cancer, inflammation and infectious disease, including in cattle, remains to 
be further investigated. 
KEGG pathways for biosynthesis of amino acids were identified as deiminated in serum-EVs 
only. This may be of considerable interest for comparative metabolic studies, particularly as amino 
acid assessment for mammalian metabolism and for research into ageing and disease has received 
some attention [242]. In dairy cows, these pathways are studies as they are of importance for 
understanding of optimization of diets and increased efficiency of microbial protein synthesis [243]. 
Enrichment for deiminated proteins in this KEGG pathway has previously been identified in alligator 
serum-EVs [93] as well as in cetacean sera [96] by our group, while mechanisms for deimination in 
this pathway remain to be elucidated. 
The presence of deiminated histones H2A, H2B, H3 and H4 was identified in serum-EVs only, 
but not in whole bovine serum. Interestingly, a similar EV-mediated export of deiminated histones, 
as observed in cow serum-EVs in the current study, was recently identified in the naked mole-rat, an 
animal with unusual immunological and metabolic traits [98], as well as in alligator, also an animal 
with unusual antimicrobial, including anti-viral responses [93]. Deiminated histone H3 is commonly 
used as an indicator for neutrophil extracellular trap formation (NETosis) [31,244], which has been 
related to PAD4 and implicated in anti-viral responses in cattle respiratory syncytial virus disease 
[42], in response to parasitic infections in cattle [245–247] as well as in response to certain antibiotics 
[248]. Interestingly, in crocodilians, extracellular histones H2A and H4 have been identified to act as 
inhibitors of viral (HIV) infection in vitro [249], although roles for post-translational deimination 
were not assessed. Anti-microbial effects for histones have furthermore been observed in teleost fish 
mucosal immunity for H2A [250] as well as for deiminated histone H3 [15]. Histone H3 deimination 
has furthermore been linked to inflammatory and hypoxic responses during CNS regeneration in 
avian and murine models [25,26]. Histone deimination is also a known epigenetic mechanism in 
cancer [11,231,233]. The multifaceted functions of histones in immunity, including via post-
translational regulation, such as deimination identified here, remains to be further investigated in 
cattle, including in relation to possible roles in anti-viral and other anti-pathogenic or disease related 
responses.  
The present study highlights novel aspects of protein moonlighting in immunity and 
metabolism of cattle, via post-translational deimination, including via EV-mediated transport. Our 
findings indicate differences in physiological and pathological pathways for deiminated proteins in 
serum-EVs, compared with whole serum, and may shed light on pathways underlying a number of 
pathological and anti-pathogenic (viral, bacterial, parasitic) pathways, with putative translatable 
value to human pathologies, zoonotic diseases and development of therapies for infections, including 
anti-viral therapies. While these data fall short of directing immediate clinical intervention for human 
disease, they do mandate further study of deimination in future work of broader scope and pre-
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clinical focus. For example, deimination will need further exploration as an additional diversification 
mechanism of ultralong CDR3 “cattlebodies” that have shown remarkable reach for broad viral 
neutralization. Also, importance for PADs in host-pathogen interactions, including in viral infections 
and in relation to COVID-19, may be of considerable importance and needs to be further investigated.  
4. Materials and Methods  
4.1. Serum Sampling from Cow 
Blood was collected from the jugular vein of three healthy 5 months old Holstein breed steer and 
serum was prepared following clotting of blood for 2 h at room temperature (RT), by centrifugation 
for five minutes at 200× g. Sample collection was conducted under Texas A&M Institutional Animal 
Care and Use Protocol # 2015-078. Serum was aliquoted and kept at –80 °C until used. These samples 
were excess from a distinct study protocol and thus no animals needed to be purchased or euthanized 
for the study described here, consistent with the ethical principle of replacement, reduction and 
refinement. 
4.2. Isolation of Extracellular Vesicles and Nanoparticle Tracking Analysis (NTA) 
Serum-EVs were isolated from serum of individual animals (n = 3), using sequential 
centrifugation and ultracentrifugation in accordance to previously established protocols [17,46,98] 
and according to the recommendations of MISEV2018 (the minimal information for studies of 
extracellular vesicles 2018; [251]). For each individual EV preparation, 100 μL of bovine serum were 
diluted 1:5 in Dulbecco’s PBS (DPBS, ultrafiltered using a 0.22 μm filter, before use) and then 
centrifuged at 4000× g for 30 min at 4 °C, to ensure the removal of aggregates and apoptotic bodies. 
Thereafter the supernatants were collected and centrifuged further, using ultracentrifugation at 
100,000× g for 1 h at 4 °C. The EV-enriched pellets were resuspended in 1 mL DPBS and 
ultracentrifuged again at 100,000× g for 1 h at 4 °C. The resulting washed EV pellets were then 
resuspended in 100 µL DPBS and frozen at –80 °C until further use. For EV size distribution profiles 
and EV quantification, NTA analysis was carried out using the NanoSight NS300 system (Malvern 
Panalytical, Malvern, UK), which analyses particle size based on Brownian motion. The EV samples 
were diluted 1/100 in DPBS (10 μL of EV preparation diluted in 990 μL of DPBS) and applied to the 
NanoSight using a syringe pump to ensure continuous flow of the sample. For each sample, five 60 
second videos were recorded, keeping the number of particles per frame in-between 40 to 60. 
Replicate histograms were generated from the videos, using the NanoSight software 3.0 (Malvern), 
representing mean and confidence intervals of the 5 recordings for each sample.  
4.3. Transmission Electron Microscopy (TEM) 
A pool of EVs, isolated from serum of the three individual animals as described above, was used 
for morphological analysis using TEM. Following isolation, the EVs were resuspended in 100 mM 
sodium cacodylate buffer (pH 7.4) and a drop (~3–5 μL) of the suspension was placed onto a grid 
with previously glow discharged carbon support film. After the suspension had partly dried, the EVs 
were fixed by placing the grid onto a drop of a fixative solution (2.5% glutaraldehyde in 100 mM 
sodium cacodylate buffer (pH 7.0)) for 1 min at room temperature and washed afterwards by 
touching the grid to the surface of three drops of distilled water. Excess water was removed by 
touching the grid to a filter paper. Next, the EVs were stained with 2% aqueous Uranyl Acetate 
(Sigma-Aldrich) for 1 min, the excess stain was removed by touching the grid edge to a filter paper 
and the grid was let to dry. Imaging of EVs was performed using a JEOL JEM 1400 transmission 
electron microscope (JEOL,Tokyo, Japan) operated at 80 kV at a magnification of 30,000× to 60,000×. 
Digital images were recorded using an AMT XR60 CCD camera (Deben UK Limited, Bury Saint 
Edmunds, UK). 
4.4. Isolation of Deiminated Proteins in Serum and EVs using F95-enrichment 
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Immunoprecipitation and isolation of deiminated proteins in serum and serum-derived EVs was 
carried out using the Catch and Release® v2.0 immunoprecipitation kit (Merck, UK) in conjunction 
with the F95 pan-deimination antibody (MABN328, Merck), which has been developed against a 
deca-citrullinated peptide and specifically detects proteins modified by citrullination [252]. Bovine 
serum pools of the three individual animals (3 × 25 μL) were used for F95-enrichment from whole 
serum, while for EVs, total protein was first extracted from the pool of EVs derived from 3 animals 
(EV pellets derived from 100 μL serum per animal), using RIPA+ buffer (Sigma, UK). Following 
application of RIPA+ buffer, the EVs were incubated on ice for 2 h followed by centrifugation at 
16,000× g for 30 min to collect the protein containing supernatant. Thereafter, immunoprecipitation 
(F95-enrichment) was carried out overnight on a rotating platform at 4 °C. The F95 bound proteins 
were eluted using denaturing elution buffer (Merck), according to the manufacturer’s instructions 
(Merck) and diluted 1:1 in Laemmli sample buffer. The F95-enriched eluates from whole serum and 
serum -EVs were then analyzed by SDS-PAGE, followed by silver staining, Western blotting or LC-
MS/MS. 
4.5. Western Blotting Analysis 
Bovine serum and serum-EVs were diluted 1:1 in denaturing 2× Laemmli sample buffer 
(containing 5% beta-mercaptoethanol, BioRad, Kidlington, UK) and boiled for 5 min at 100 °C. 
Proteins were separated by SDS-PAGE using 4%-20% gradient TGX gels (BioRad UK). Western 
blotting was carried out using the Trans-Blot®  SD semi-dry transfer cell (BioRad, UK); even transfer 
was assessed by staining the membranes with PonceauS (Sigma, UK). Blocking was performed for 1 
h at room temperature using 5% bovine serum albumin (BSA; Sigma, UK), in Tris buffered saline 
(TBS) containing 0.1% Tween20 (BioRad, UK; TBS-T). Following blocking the membranes were 
incubated overnight at 4 °C on a shaking platform with the primary antibodies, which were diluted 
in TBS-T. For detection of deiminated/citrullinated proteins, the F95 pan-deimination antibody was 
used (MABN328, Merck, 1/1000). For detection of PAD proteins in bovine serum, the following anti-
human PAD antibodies were used: anti-PAD2 (ab50257, Abcam, Cambridge, 1/1000); anti-PAD3 
(ab50246, Abcam, 1/1000) and anti-PAD4 (ab50247, Abcam, 1/1000), and have previously been shown 
to cross-react with PAD homologues in a range of taxa [15–17,25,26,92,93,96–99]. EV isolates were 
blotted against two EV-specific markers: CD63 (ab216130, 1/1000) and Flotillin-1 (Flot-1, ab41927, 
1/2000), for characterisation of EVs. After primary antibody incubation the membranes were washed 
for 3 × 10 min in TBS-T at RT and incubated for 1 h, at RT with HRP-conjugated secondary antibodies 
(anti-rabbit IgG (BioRad) or anti-mouse IgM (BioRad) respectively, diluted 1/3000 in TBS-T). The 
membranes were then washed in TBS-T for 5 × 10 min and positive proteins bands were visualized 
digitally, using enhanced chemiluminescence (ECL, GE Healthcare, Amersham Pl, Little Chalfont, 
UK) and the UVP BioDoc-ITTM System (Thermo Fischer Scientific, Hemel Hempstead, UK).  
4.6. Silver Staining 
F95-enriched protein eluates from bovine serum and serum-EVs were silver stained following 
SDS-PAGE (using 4%–20% gradient TGX gels, BioRad, UK) under reducing conditions, using the 
BioRad Silver Stain Plus Kit (1610449, BioRad, UK), according to the manufacturer's instructions 
(BioRad). 
4.7. Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) Analysis of Deiminated Protein 
Candidates 
F95-enriched eluates from bovine serum and serum-EVs respectively, were analyzed by liquid 
chromatography with tandem mass spectrometry (LC-MS/MS), according to previously described 
methods [93,99]. For LC-MS/MS analysis, the F95-enriched eluates were run 0.5 cm into a 12% TGX 
gel (BioRad, UK), the band cut out, trypsin digested and subjected to proteomic analysis on a Dionex 
Ultimate 3000 RSLC nanoUPLC (Thermo Fisher Scientific Inc, Waltham, MA, USA.) system and a 
QExactive Orbitrap mass spectrometer (Thermo Fisher Scientific Inc, Waltham, MA, USA) according 
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to previously described methods [93,99]. In brief, peptides were separated by reverse-phase 
chromatography and a Thermo Scientific reverse-phase nano Easy-spray column (Thermo Scientific 
PepMap C18, 2 µm particle size, 100A pore size, 75 µm i.d. × 50 cm length). First, a pre-column 
(Thermo Scientific PepMap 100 C18, 5 µm particle size, 100A pore size, 300 µm i.d. × 5 mm length) 
was used for loading the peptides from the Ultimate 3000 autosampler, in the presence of 0.1% formic 
acid for 3 min (flow rate 10 µL/min). Therafter, peptides were eluted from the pre-column onto the 
analytical column (solvent A = water + 0.1% formic acid; solvent B = 80% acetonitrile, 20% water + 
0.1% formic acid). A linear gradient of 2%–40% B was applied for 30 minutes. An easy-Spray source 
(Thermo Fischer Scientific Inc., Waltham, MA, USA) as used to spray the LC eluant into the mass 
spectrometer. The m/z values of the eluting ions were measured using an Orbitrap mass analyzer. 
The resolution was set at 70,000 and scanning was performed at m/z 380–1500. Fragment ions were 
automatically isolated and generated based on data dependent scans (top 20) in the HCD collision 
cell by higher energy collisional dissociation (HCD, NCE:25%). The resulting fragment ions were 
measured using the Orbitrap analyzer, set at a resolution of 17500. Ions that were singly charged, or 
with unassigned charge states, were excluded from selection for MS/MS. Furthermore, a dynamic 
exclusion window of 20 seconds was applied. The Protein Discoverer (version 2.1., Thermo Scientific) 
was used to process the data post-run and the MS/MS data was thereafter converted to mgf files. For 
identification of deiminated protein hits, the files were then submitted to the Mascot search algorithm 
(Matrix Science, London, UK) and searched against the UniProt Bos taurus_ 20170607 database (24148 
sequences; 40594 residues) and Bos_primigenius primigenius_20191209 database (54 sequences; 14783 
residues), as well as a common contaminant sequences (123 sequences; 40594 residues). Fragment 
and peptide mass tolerances and were set at 0.1 Da and 20 ppm, respectively. The peptide cut-off 
score was set at 31 and significance at p < 0.05 (carried out by Cambridge Proteomics, Cambridge, 
UK).  
4.8. Protein–Protein Interaction Network Analysis 
For the identification and prediction of putative protein–protein interaction networks for 
deiminated proteins identified in bovine serum and serum-EVs, STRING analysis (Search Tool for 
the Retrieval of Interacting Genes/Proteins; https://string-db.org/) was used. Protein networks were 
built based on the protein IDs and using the function of “search multiple proteins” in STRING, 
choosing “Bos taurus” for the species database. For analysis, “medium conficence” and “basic 
settings” were selected and the colour lines connecting nodes indicated the following evidence-based 
interactions for the network edges: “known interactions”, which are based on curated databases or 
experimentally determined interactions; “predicted interactions”, which are based on protein 
homology, co-expression, gene fusion, gene neighborhood, gene co-occurrence, or established by text 
mining. 
4.9. Phylogenetic Comparison of Bos PADs with Human PADs 
A neighbor-joining phylogeny tree was constructed using Clustal Omega 
(https://www.ebi.ac.uk/Tools/msa/clustalo/) based on sequence alignment of amino acid sequences 
for bovine PADs 1-6 (PAD1, NP_001094742.1; PAD2, NP_001098922.1; PAD3, XP_010800991.1; PAD4, 
NP_001179102.1 and PAD6, XP_002685843.1) compared with human PADs 1-6 (PAD1, NP_037490.2; 
PAD2, NP_031391.2; PAD3, NP_057317.2; PAD4, NP_036519.2 and PAD6, NP_997304.3). 
2.10. Statistical Analysis 
The histograms and graphs were prepared using the Nanosight 3.0 software (Malvern 
Panalytical) and GraphPad Prism version 7 (GraphPad Software, San Diego, CA, USA). NTA curves 
represent mean and standard error of mean (SEM), indicated by confidence intervals. STRING 
analysis (https://string-db.org/) was used for prediction of protein–protein interaction networks. 
Significance was considered as p ≤ 0.05. 
5. Conclusions 
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In the current study we report for the first time deimination profiles of serum and serum-EVs of 
Bos taurus. Post-translational deimination of key immune, metabolic and nuclear proteins was 
identified and these related to KEGG pathways for a number of immunological pathways with 
relevance to viral, bacterial and parasitic infections, to chronic and autoimmune diseases, as well as 
a range of metabolic pathways. Our findings highlight novel aspects of protein moonlighting in 
immunity and metabolism of cattle, via post-translational deimination, including via EV-mediated 
transport. 
While these data fall short of directing immediate clinical intervention for human disease, they 
do mandate further study of deimination as an additional diversification mechanism of ultralong 
CDR3 “cattlebodies” that have shown remarkable reach for broad viral neutralization. This study 
limitation of this comparative biochemical basic science must be addressed in future work of broader 
scope and pre-clinical focus. Furthermore, transcriptomics data revealing downregulation in PAD4 
mRNA levels in SARS-CoV-2 infected patient’ lung biopsies, compared to healthy controls 
(https://www.ncbi.nlm.nih.gov/bioproject/PRJNA615032), indicates importance for PADs in host-
virus interactions in COVID-19 and will need to be further explored. 
EVs research in comparative immunology and veterinary sciences is a rapidly growing field and 
while EVs have been previously assessed in cattle, this study is the first to characterise deiminated 
protein signatures in bovine serum and serum-EVs. The identification of post-translational 
deimination and EV-mediated communication in bovine immunity and physiology, revealed here, 
contributes to current understanding of protein moonlighting functions and EV-mediated 
communication in cattle, providing novel insight into their unusual immune systems and 
physiological traits. Our findings may shed light on pathways underlying a number of pathological 
and anti-pathogenic, including anti-viral, pathways, with putative translatable value to human 
pathologies, zoonotic diseases and development of therapies for infections, including anti-viral 
therapies. 
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